Cannabis vs. Pharmaceutical Sales
View this email in your browser
Cannabis Sales Impact Big Pharma Profits
May 21, 2017
Medical Cannabis Could Take a Big Bite Out of Pharmaceutical Sales
  • Cannabis is an effective treatment for conditions including chronic pain, post-traumatic stress disorder (PTSD), sleep disorders, anxiety, epilepsy, nerve pain, chemotherapy-induced nausea and vomiting, Tourette’s Syndrome, and glaucoma. *
  • Americans spent an estimated $40.1 billion on prescription medications in 2016 to treat these conditions, and expenditures are forecast to grow to more than $44.1 billion by 2019.
  • Three conditions which drove the highest prescription drug expenditures in 2016 were chronic pain ($14.3 billion), PTST ($10.6 billion), and sleep disorders ($6.13 billion).
  • Prescription drug use, most commonly associated with medical cannabis, falls an average of 11% in states with legalized medical cannabis.
  • If medical cannabis use were legalized nationally in 2016, an 11% decline in prescription drug use would have equated to an estimated $4.4 billion in reduced prescription drug spending, and an estimated $4.9 billion in 2019.
  • Between 2016 and 2020, the 11% reduction in prescription drug spending would be a combined $18.5 billion.
  • The impact that cannabis legalization will have on the pharmaceutical industry underscores why pharmaceutical companies have been so strongly opposed to the expansion of legal cannabis.  For example, Insys, maker of the opioid Fentanyl Subsys, funded the 2016 anti-cannabis legalization campaign in Arizona.  Insys’ financial support of the opposition helped defeat the initiative on election day.

* According to the National Academies of Science

It is important to get the most up-to-date market research as soon as it is available.

Enjoy the full breadth of New Frontier Data’s market research with a SUBSCRIPTION!

Gain access to our entire current library of reports, a $10,000 value, and first access to all upcoming reports and studies.

For an annual cost of $2,499, you will receive almost $10,000 worth of industry intelligence, including access to the largest library of legal cannabis research available in the world. 

  • Get access to New Frontier Data’s entire current library of reports
  • Gain first access to all upcoming reports and position papers. Upcoming topics include:
    • Gender Diversity and the Role of Women in Cannabis
    • Finance and Investing in Cannabis
    • California Delivery Services
    • Cultivation
    • Energy Study Part II
    • Cannabis Testing Study
    • Hospitality & CannaTourism
    • Global Markets: Canada
    • Global Markets: International Compendium
    • State Markets: Washington DC
    • State Markets: New Mexico
    • State Markets: Michigan
    • State Markets: Connecticut
  • Receive free access to Equio, New Frontier Data’s business intelligence platform, and receive daily content from our industry experts
Subscribe Today

New Product Release Limited-Time Offer

Projections in our 2017 Annual Report Featured...
Read the full article here.
Federal Appeals Court Sidesteps Major Marijuana Ruling
US News
Israeli Health Ministry announces directives relaxing medical cannabis restrictions

Read the full article here.
Inside Story on Prominent National DA Group’s Pot Policy Paper
New Jersey Lawmakers Consider Legalizing Marijuana

Read the full article here.
Copyright © 2017 Frontier Financial Group, Inc., dba New Frontier Data, All rights reserved.

Our mailing address is:

1990 M Street, NW, Suite 530
Washington, DC 20036

535 16th Street, Suite 620
Denver, CO 80202

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list